Xilio Therapeutics strengthens its leadership team with the appointment of Dr. Houvras, a veteran in translational medicine and immuno-oncology, to oversee clinical development.
Appointment of a new Chief Medical Officer with extensive experience may strengthen clinical development capabilities but does not directly alter financials or guidance.
Xilio Therapeutics has named Dr. Houvras as its new Chief Medical Officer to lead clinical development and immuno-oncology initiatives. The appointment leverages his two decades of experience across academic and industry research institutions to bolster the company's pipeline.
Dr. Houvras will oversee clinical development, translational medicine, and immuno-oncology research efforts.